Insider · CIK 0001563420
Seth Lederman
Files at TNXP (Tonix Pharmaceuticals Holding Corp.). First filing May 15, 2025, latest Aug 31, 2026.
In brief
Seth Lederman files SEC Form 4 as CEO and director at TNXP (Tonix Pharmaceuticals Holding Corp.). Since May 15, 2025, Seth Lederman has reported 5 open-market buys worth $459k and 0 open-market sells worth $0, the latest filed on Aug 31, 2026.
A track record needs three past buys with six months of prices behind them; Seth Lederman has 2, so none is measured yet.
The newest scored trade: bought $28k of TNXP on Aug 27, 2026, filed Aug 31, 2026, scored 57 (moderate). In the last 12 months: 4 buys worth $373k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TNXP: Tonix Pharmaceuticals Holding Corp.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Tonix Pharmaceuticals Holding Corp. | $28k 2,000 shares | +22% | +43% from low-58% from high | |
| 80Strong | Tonix Pharmaceuticals Holding Corp. | $59k 5,000 shares | +125% | +4% from low-81% from high | |
| 52Moderate | TNXPbuy Tonix Pharmaceuticals Holding Corp. | $63k 5,000 shares | +33% | +14% from low-78% from high | |
| 65Notable | TNXPbuy Tonix Pharmaceuticals Holding Corp. | $223k 15,000 shares | first purchase | +7% from low-77% from high | |
| 44Moderate | TNXPbuy Tonix Pharmaceuticals Holding Corp. | $86k 4,000 shares | first purchase | - |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | POpen-market purchase Common Stock, $0.001 par valueindirect: By IRA Account | +2,000 | $13.79 | $28k | 11,005 | 44 d ago |
| Jun 9, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | POpen-market purchase Common Stock, $0.001 par value | +5,000 | $11.79 | $59k | 9,005 | Jun 9, 2026 |
| Mar 31, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | POpen-market purchase Common Stock, $0.001 par valueindirect: By IRA Account | +5,000 | $12.62 | $63k | 20,001 | Apr 1, 2026 |
| Mar 18, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | POpen-market purchase Common Stock, $0.001 par valueindirect: By IRA Account | +15,000 | $14.89 | $223k | 15,001 | Mar 18, 2026 |
| Feb 24, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | AGrant or award Stock Optionderivative | +134,504 | $0.00 | $0 | 134,504 | Feb 26, 2026 |
| Feb 24, 2026 | TNXP Tonix Pharmaceuticals Holding Corp. | AGrant or award Stock Optionderivative | +134,503 | $0.00 | $0 | 134,503 | Feb 26, 2026 |
| May 15, 2025 | TNXP Tonix Pharmaceuticals Holding Corp. | POpen-market purchase Common Stock, $0.001 par value | +4,000 | $21.55 | $86k | 4,005 | May 15, 2025 |
| Feb 5, 2025 | TNXP Tonix Pharmaceuticals Holding Corp. | JOther Common Stock, $0.001 par value | -5 | $3.38 | $18 | 5 | Feb 27, 2025 |
| Feb 5, 2025 | TNXP Tonix Pharmaceuticals Holding Corp. | JOther Common Stock, $0.001 par valueindirect: By IRA Account | -0 | $3.30 | $1 | 1 | Feb 27, 2025 |
| Feb 5, 2025 | TNXP Tonix Pharmaceuticals Holding Corp. | JOther Common Stock, $0.001 par valueindirect: By Spouse | -1 | $0.15 | $0 | 0 | Feb 27, 2025 |
| Feb 25, 2025 | TNXP Tonix Pharmaceuticals Holding Corp. | AGrant or award Stock Optionderivative | +123,958 | $0.00 | $0 | 123,958 | Feb 27, 2025 |
| Feb 25, 2025 | TNXP Tonix Pharmaceuticals Holding Corp. | AGrant or award Stock Optionderivative | +123,958 | $0.00 | $0 | 123,958 | Feb 27, 2025 |
| Feb 27, 2024 | TNXP Tonix Pharmaceuticals Holding Corp. | AGrant or award Stock Optionderivative | +235,320 | $0.00 | $0 | 235,320 | Feb 29, 2024 |
| Feb 27, 2024 | TNXP Tonix Pharmaceuticals Holding Corp. | AGrant or award Stock Optionderivative | +1,903,680 | $0.00 | $0 | 1,903,680 | Feb 29, 2024 |
| Feb 27, 2024 | TNXP Tonix Pharmaceuticals Holding Corp. | AGrant or award Stock Optionderivative | +1,309,911 | $0.00 | $0 | 1,309,911 | Feb 29, 2024 |
Questions about Seth Lederman
Answered from the filings on this page, as of the latest one.
Is Seth Lederman buying or selling?
In the last 12 months Seth Lederman reported 4 open-market buys worth $373k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $28k of TNXP on Aug 27, 2026. Grants, option exercises and tax withholding are not counted.
How did Seth Lederman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Seth Lederman has 2.
Where does Seth Lederman file Form 4?
Seth Lederman has filed Form 4 at TNXP (Tonix Pharmaceuticals Holding Corp.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.